PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesUrogenital Diseases+ [7]

Active Indication

Breast CancerBRCA Mutation Castration-Resistant Prostate CancerMetastatic castration-resistant prostate cancer+ [33]

Inactive Indication

Advanced Endometrial CarcinomaChildhood Malignant Solid NeoplasmChronic Lymphocytic Leukemia+ [18]

Originator Organization

BioMarin Pharmaceutical, Inc.

Active Organization

Pfizer Inc.Pfizer Europe MA EEIG

Zenith Epigenetics Ltd.

+ [5]

Inactive Organization

Calithera Biosciences, Inc.MediVation, Inc.

Drug Highest PhaseApproved

First Approval Date

US (16 Oct 2018),

Germline BRCA-mutated, HER2-negative metastatic breast cancer

RegulationPriority Review (US)

Structure

Molecular FormulaC26H22F2N6O4S

InChIKeyQUQKKHBYEFLEHK-QNBGGDODSA-N

CAS Registry1373431-65-2

118

Clinical Trials associated with Talazoparib Tosylate

NCT04982848 / Not yet recruitingNot Applicable

A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Talzenna(Registered)

Talzenna will be approved for the treatment of gBRCA advanced breast cancer in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing surveillance is required to determine any problems or questions associated with Talzenna after marketing in Korea, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of Talzenna will be observed.

Start Date31 Dec 2024

Sponsor / Collaborator

Pfizer Inc.

CTRI/2024/10/076008 / Not yet recruitingNot ApplicableIIT

Retrospective observational study of safety and efficacy of Talazoparib in BRCA1/2 or PALB2 mutation breast cancer. - Nil

Start Date10 Nov 2024

Sponsor / Collaborator-

NCT05873192 / Not yet recruitingPhase 2IIT

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate Cancer

To learn about the effectiveness of adding talazoparib to the standard of care treatment combination of androgen ablation therapy (hormone therapy, also known as ADT) and enzalutamide in patients with prostate cancer that has spread into the lymph nodes.

Start Date30 Sep 2024

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

100 Clinical Results associated with Talazoparib Tosylate

100 Translational Medicine associated with Talazoparib Tosylate

100 Patents (Medical) associated with Talazoparib Tosylate

500

Literatures (Medical) associated with Talazoparib Tosylate

01 Mar 2025·CURRENT PHARMACEUTICAL DESIGN

PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer Treatment

Article

Author: Shah, Kamal ; Bhati, Akash ; Dewangan, Hitesh Kumar ; Aggarwal, Shagun ; Sharma, Navneet

Abstract::

Breast cancer stands on the second position in the world in being common and women happen to have it with high rate of about five-folds around the world. The causes of occurrence can matter with different humans be it external factors or the internal genetic ones. Breast cancer is primarily driven by mutations in the BRCA1 and BRCA2 susceptibility genes. These BC susceptibility genes encode proteins critical for DNA homologous recombination repair (HRR). Poly (ADP ribose) polymerases (PARP) are the essential enzymes involved in the repairing of the damaged DNA. So the inhibition of these inhibitors can be considered as the promising strategy for targeting cancers with defective damage in the deoxyribonucleic acid. Olaparib and talazoparib are PARP inhibitors (PARPi) are being employed for the monotherapies in case of the deleterious germline HER2-negative and BRCA-mutated breast cancer. The potency of PARP for trapping on DNA and causes cytotoxicity may have difference in the safety and efficacy with the PARPi. The PARPi have been found its place in the all different types of breast cancers and have shown potential benefits. The purpose of this review is to provide an update on the oral poly(ADP-ribose) polymerase (PARP) inhibitors for the improvement in the treatment and management of breast cancer.

01 Jan 2025·Translational Oncology

Indirect targeting of MYC and direct targeting in combination with chemotherapies are more effective than direct mono-targeting in triple negative breast cancer

Article

Author: Mekonnen, Negesse ; Song, Kyoung ; Yang, Hobin ; Shin, Young Kee ; Choi, Yoon-La ; Rajasekaran, Nirmal

MYC amplification is disproportionally elevated in triple-negative breast cancer (TNBC) compared to other subtypes of breast cancer. Indeed, MYC has long been considered an undruggable oncogene using conventional drug design strategies or small molecules. We hypothesized that targeting MYC using asymmetric siRNA (asiRNA) alone or in combination with chemotherapeutic agents or indirectly via BRD4 and RRM2, may curb its oncogenic behavior. We developed paclitaxel-, doxorubicin-, and cisplatin-resistant MDA-MB-231 cells to study MYC's role in upregulating DNA repair genes during drug resistance development. Our results showed that the knockdown of either MYC or RRM2 downregulated both RAD51 and PARP1 but increased γH2AX. The cytotoxic effect of RRM2 knockdown was significantly (p < 0.05) higher than that of direct MYC knockdown. The knockdown of BRD4 was more effective than the direct knockdown of MYC in downregulating MYC protein. The combined use of asiRNA-VP (Vinylphosphonate) with dacomitinib or talazoparib was synthetic lethal in TNBC cell lines. Compared to chemotherapy-sensitive cells, resistant cells showed overexpression of MYC, RRM2, RAD51, and PARP1 proteins upon chemotherapy treatment, but downregulated in cells treated with asiRNA-VP combination. We confirmed that MYC knockdown upregulated cFLIP, BCL2, STAT1, pSTAT1, STAT2, and cleaved saspase-3 in both TNBC and non-small cell lung cancer (NSCLC) cell lines. Finally, we recommend a combination treatment approach that synergizes with MYC inhibition rather than monotherapy or indirect targeting via upstream regulators such as the BRD4 and RRM2 genes or selective modulation at the protein level to suppress anti-apoptotic genes (cFLIP and BCL2) at the same time.

01 Dec 2024·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Isoxazole compounds: Unveiling the synthetic strategy, in-silico SAR & toxicity studies and future perspective as PARP inhibitor in cancer therapy

Review

Author: Pal, Dilipkumar ; Malik, Udita

Latest developments in cancer treatment have shed a light on the crucial role of PARP inhibitors that enhance the treatment effectiveness by modifying abnormal repair pathways. PARP inhibitors, such as Olaparib, Rucaparib, Niraparib, and Talazoparib have been approved in a number of cancers including BRCA 1/BRCA2 associated malignancies although there are many difficulties as therapeutical resistance. Besides the conventional synthetic drugs, natural compounds such as flavones and flavonoids have been found to be PARP inhibitors but only in preclinical studies. Isoxazole is very important class of potential candidates for medicinal chemistry with anti-cancer and other pharmacological activities. At present, there are no approved PARP inhibitors of isoxazole origin but their ability to hit many pathways inside the cancer cells points out on its importance for future treatments design. In drug development, isoxazoles are helpful because of the molecular design flexibility that may be enhanced using various synthetic approaches. This review highlights the molecular mechanisms of PARP inhibition, importance of isoxazole compounds and present advances in their synthetic strategies that demonstrate promise for these agents as new anticancer drugs. It emphasizes that isoxazole-based PARP inhibitors compounds could be novel anti-cancer drugs. Through this review, we hope to grow a curiosity in additional explorations of isoxazole-based PARP inhibitors and their applications in the trends of novel insights towards precision cancer therapy.

News (Medical) associated with Talazoparib Tosylate

19 Nov 2024

·endpts.com

NICE has 'done all we can' to negotiate for Enhertu coverage, reaffirms decision not to recommend

The UK’s drug pricing body has affirmed its earlier decision not to recommend coverage of AstraZeneca and Daiichi Sankyo’s breast cancer treatment Enhertu. “As we’ve always made clear, the fastest and only guaranteed way to get medicines like Enhertu to the patients who need them is for companies to offer a fair price,” National Institute for Health and Care Excellence (NICE) Chief Executive Samantha Roberts said in a statement Tuesday . “We have done all we can to try and achieve that.” The UK’s National Health Service uses NICE’s recommendations to determine what treatments it pays for. It recommended against coverage of Enhertu earlier this summer, but kept negotiating with the companies. The UK group said that it and the country’s National Health Service tried to “offer as much flexibility as possible” but that the companies did not put forth “a cost-effective price.” Spokespeople for AstraZeneca and Daiichi didn’t immediately respond to a request for comment on NICE’s position. NICE compared the drug to Pfizer’s similar HER2-targeting cancer drug, Talzenna, for which it used the same assessment as Enhertu and ended up recommending it. Not recommending Enhertu breaks a streak of 21 consecutive positive recommendations for breast cancer treatments, NICE said. The decision was first handed down in July , after Enhertu became the first licensed product in the UK to treat the newly-defined HER2-low population. Those patients were previously categorized as HER2-negative, but have trace amounts of the protein. NICE estimates that there are about 1,000 women in England and Wales who would qualify for the drug. Enhertu is a rising star in AstraZeneca’s oncology portfolio, recording more than $1.4 billion in sales through the first nine months of the year. That includes $510 million in the third quarter , a 50% jump from the third quarter of 2023. None of AstraZeneca’s other cancer drugs saw greater revenue growth in the quarter.

Drug ApprovalAccelerated Approval

14 Oct 2024

·pmlive.com

Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer

Pfizer has announced positive overall survival (OS) results from a late-stage study of its prostate cancer combination treatment. The phase 3 TALAPRO-2 trial has been evaluating the drugmaker’s PARP inhibitor Talzenna (talazoparib) in combination with its Astellas-partnered androgen receptor pathway inhibitor (ARPI) Xtandi (enzalutamide) in patients with metastatic castration-resistant prostate cancer (mCRPC). Results showed a statistically significant and clinically meaningful OS improvement for patients receiving the combination in the ‘all-comers’ cohort, as well as those with homologous recombination repair (HRR) gene-mutated mCRPC, compared to Xtandi alone. Talzenna plus Xtandi is now the first and only PARP inhibitor/ARPI combination to significantly improve survival in mCRPC patients regardless of mutation status, noted Roger Dansey, Pfizer’s chief development officer, oncology. The clinically meaningful improvement in radiographic progression-free survival from the prior primary analysis of the trial was also maintained in both cohorts, and the safety profile of the combination was generally consistent with the known safety profile of each drug. Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.4 million new cases diagnosed in 2022. Up to 20% of patients develop mCRPC, a form of the disease that has spread beyond the prostate gland and has progressed despite medical or surgical treatment to lower testosterone, within five to seven years of diagnosis. Talzenna plus Xtandi was approved by the US Food and Drug Administration in June 2023 for use in adults with HRR gene-mutated mCRPC. The combination was also approved by the European Commission in January 2024 to treat mCRPC in adults for whom chemotherapy is not clinically indicated. The new data from TALAPRO-2 will now be shared with global health authorities to support potential label expansion. Global lead investigator for the trial Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, said: “These OS results indicate potentially practice-changing efficacy for Talzenna in combination with Xtandi for men with mCRPC. “mCRPC is the most advanced and aggressive stage of the disease, and the TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options.”

Clinical ResultPhase 3Drug Approval

10 Oct 2024

·www.prnewswire.com

Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Metastatic Castration-Resistant Prostate Cancer (mCRPC) refers to prostate cancer that has spread (metastasized) to other parts of the body and continues to progress despite treatments that lower testosterone levels (androgen deprivation therapy or ADT) major pharmaceutical companies are heavily investing in research and development of new treatments, including immunotherapy (e.g., sipuleucel-T) and targeted therapies, which are seen as the next frontier in treating mCRPC. The use of precision medicine to identify genetic profiles in patients has further expanded the potential for targeted treatment. LAS VEGAS , Oct. 10, 2024 /PRNewswire/ -- DelveInsight's ' Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline mCRPC therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the mCRPC pipeline domain. Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report DelveInsight's mCRPC pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for mCRPC treatment. Key mCRPC companies such as Regeneron Pharmaceuticals, AstraZeneca, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Astellas Pharma, Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Forma Therapeutics, Inc., HALDA THERAPEUTICS INC., Tavanta Therapeutics, Lantheus, Pfizer, AB Science, Syntrix Pharmaceuticals, Exelixis, Laekna Therapeutics Shanghai Co. Ltd., Cardiff Oncology, Ipsen, Norroy Bioscience, Astellas Pharma, Novartis, Johnson & Johnson, Tempest Therapeutics, and others are evaluating new mCRPC drugs to improve the treatment landscape. Promising mCRPC pipeline therapies such as REGN 4336, Capivasertib, Deutenzalutamide, ZEN003694, Abemaciclib, Enfortumab vedotin, Talazoparib, I-131-1095, Pelgifatamab corixetan, AC176, HP518, FT-7051, HLD-0915, TAVT-45, PNT2002, Mevrometostat, Masitinib, SX-682, XL092, LAE001, Onvansertib, Tazemetostat, 177Lu-NYM032, PRL-02, 225 Actinium PSMA 617, ARX51, TPST-1120, and others are under different phases of mCRPC clinical trials. In October 2024, Curium announced that it had entered into a strategic partnership with PDRadiopharma Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T. The two agents 177Lu-PSMA-I&T and 64Cu-PSMA-I&T target prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells and are being investigated for prostate cancer treatment and diagnostics. In July 2024, the US FDA granted fast-track designation to the prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical 225Ac-FL-020 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In July 2024, Merck and Orion Corporation announced the mutual exercise of option providing Merck global exclusive rights to Opevesostat, an investigational CYP11A1 inhibitor, for the treatment of Metastatic Castration-Resistant Prostate Cancer. In July 2024, the US FDA granted fast-track designation to the antibody-drug conjugate (ADC) BNT324/DB-1311 to potentially treat patients with unresectable advanced or metastatic castration-resistant prostate cancer (mCRPC) whose disease had progressed on or after standard systemic regimens. In July 2024, FutureChem announced that the FC-705 has received orphan drug designation from the Ministry of Food and Drug Safety (MFDS) for the treatment of prostate cancer. In June 2024, CAR T-Cell Therapy demonstrated promising results for mCRPC according to Phase I trial results. In January 2024, Lava Therapeutics announced that it has signed a clinical trial collaboration and supply agreement with Merck to evaluate its prostate cancer therapy LAVA-1207 as a combination treatment with MSD's Keytruda (pembrolizumab). In July 2024, Blue Earth Therapeutics announced the signing of a clinical research collaboration with University College London (UCL). The collaboration is centered on a Phase I/II trial designed to evaluate the safety, tolerability, radiation dosimetry, and antitumor activity of the 225Ac-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer who have previously responded to lutetium 177 (177Lu)-PSMA therapy. Request a sample and discover the recent advances in mCRPC treatment drugs @ Metastatic Castration-Resistant Prostate Cancer Pipeline Report The mCRPC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mCRPC drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the mCRPC clinical trial landscape. Metastatic Castration-Resistant Prostate Cancer Overview Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of prostate cancer that continues to grow and spread despite hormone therapy aimed at lowering testosterone levels. The term "metastatic" refers to cancer spreading to other parts of the body, such as the bones, lymph nodes, or distant organs, while "castration-resistant" indicates that the cancer no longer responds to treatments that reduce testosterone, a key driver of prostate cancer growth. mCRPC is typically more aggressive and challenging to treat than earlier stages of prostate cancer. The causes of mCRPC stem from genetic and environmental factors. Genetic mutations in the androgen receptor pathway can make cancer cells less dependent on testosterone, allowing them to thrive even under hormone-suppressing treatments. Environmental factors like diet, lifestyle, and exposure to certain chemicals may also contribute to the development and progression of prostate cancer. Symptoms of mCRPC often include pain in bones, fatigue, difficulty urinating, weight loss, and general weakness. As the cancer spreads, it can impair the function of other organs, depending on the site of metastasis. Diagnosis of mCRPC usually involves a combination of tests, including prostate-specific antigen (PSA) blood tests, imaging studies like CT scans, MRIs, or bone scans, and sometimes biopsies to confirm the spread and resistance to treatment. Treatment options for mCRPC are more complex and may include newer hormonal therapies (e.g., abiraterone, enzalutamide), chemotherapy (docetaxel or cabazitaxel), immunotherapy (e.g., sipuleucel-T), or targeted therapies such as PARP inhibitors. Bone-targeting therapies, radiation, and palliative care can also be used to manage symptoms and improve the quality of life. Treatment is typically tailored to the individual based on the extent of the disease and the patient health. Find out more about mCRPC treatment drugs @ Drugs for Metastatic Castration-Resistant Prostate Cancer Treatment A snapshot of the mCRPC Pipeline Drugs mentioned in the report: Learn more about the emerging mCRPC pipeline therapies @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials Metastatic Castration-Resistant Prostate Cancer Therapeutics Assessment The mCRPC pipeline report proffers an integral view of the mCRPC emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous Therapeutics Assessment By Molecule Type: Small molecule, Cell therapy, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Androgen receptor degradation enhancers, Antibody-dependent cell cytotoxicity, Proto-oncogene protein c-akt inhibitors, Androgen receptor antagonists, Bromodomain and extraterminal domain protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Ionizing radiation emitters, PPAR alpha antagonists. Key Metastatic Castration-Resistant Prostate Cancer Companies: Regeneron Pharmaceuticals, AstraZeneca, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Astellas Pharma, Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Forma Therapeutics, Inc., HALDA THERAPEUTICS INC., Tavanta Therapeutics, Lantheus, Pfizer, AB Science, Syntrix Pharmaceuticals, Exelixis, Laekna Therapeutics Shanghai Co. Ltd., Cardiff Oncology, Ipsen, Norroy Bioscience, Astellas Pharma, Novartis, Johnson & Johnson, Tempest Therapeutics, and others. Key Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies: REGN 4336, Capivasertib, Deutenzalutamide, ZEN003694, Abemaciclib, Enfortumab vedotin, Talazoparib, I-131-1095, Pelgifatamab corixetan, AC176, HP518, FT-7051, HLD-0915, TAVT-45, PNT2002, Mevrometostat, Masitinib, SX-682, XL092, LAE001, Onvansertib, Tazemetostat, 177Lu-NYM032, PRL-02, 225 Actinium PSMA 617, ARX51, TPST-1120, and others. Dive deep into rich insights for new drugs for mCRPC treatment, visit @ Metastatic Castration-Resistant Prostate Cancer Drugs Table of Contents For further information on the mCRPC Cancer pipeline therapeutics, reach out @ Metastatic Castration-Resistant Prostate Cancer Treatment Drugs Related Reports Metastatic Castration-Resistant Prostate Cancer Market Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCRPC companies including AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen Research & Development, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, among others. Metastatic Prostate Cancer Market Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others. Metastatic Castration-Sensitive Prostate Cancer Market Metastatic Castration-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCSPC companies including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others. Metastatic Castration-Sensitive Prostate Cancer Pipeline Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key mCSPC companies, including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Fast TrackImmunotherapyPhase 1Clinical Result

100 Deals associated with Talazoparib Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Talazoparib Tosylate	L01XX60	DB11760

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	US	Pfizer Inc.	07 Mar 2024
BRCA Mutation Castration-Resistant Prostate Cancer	JP	Pfizer Japan, Inc.	18 Jan 2024
Metastatic castration-resistant prostate cancer	EU	Pfizer Inc.	08 Jan 2024
Metastatic castration-resistant prostate cancer	IS	Pfizer Inc.	08 Jan 2024
Metastatic castration-resistant prostate cancer	LI	Pfizer Inc.	08 Jan 2024
Metastatic castration-resistant prostate cancer	NO	Pfizer Inc.	08 Jan 2024
HRR Gene-mutated Castration-Resistant Prostate Cancer	AU	Pfizer Australia Pty Ltd.	18 Nov 2019
Metastatic breast cancer	CA	PF Consumer Healthcare Canada ULC	06 Sep 2019
Hormone receptor positive breast cancer	EU	Pfizer Europe MA EEIG	20 Jun 2019
Hormone receptor positive breast cancer	IS	Pfizer Europe MA EEIG	20 Jun 2019
Hormone receptor positive breast cancer	LI	Pfizer Europe MA EEIG	20 Jun 2019
Hormone receptor positive breast cancer	NO	Pfizer Europe MA EEIG	20 Jun 2019
Germline BRCA-mutated, HER2-negative metastatic breast cancer	US	Pfizer Inc.	16 Oct 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-Resistant Prostatic Cancer	NDA/BLA	US	Pfizer Inc.	17 Feb 2023
Castration-sensitive prostate cancer	Phase 3	US	Pfizer Inc.	12 May 2021
Castration-sensitive prostate cancer	Phase 3	CN	Pfizer Inc.	12 May 2021
Castration-sensitive prostate cancer	Phase 3	JP	Pfizer Inc.	12 May 2021
Castration-sensitive prostate cancer	Phase 3	AR	Pfizer Inc.	12 May 2021
Castration-sensitive prostate cancer	Phase 3	AU	Pfizer Inc.	12 May 2021
Castration-sensitive prostate cancer	Phase 3	BE	Pfizer Inc.	12 May 2021
Castration-sensitive prostate cancer	Phase 3	BG	Pfizer Inc.	12 May 2021
Castration-sensitive prostate cancer	Phase 3	CA	Pfizer Inc.	12 May 2021
Castration-sensitive prostate cancer	Phase 3	CZ	Pfizer Inc.	12 May 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03395197 (TALAPRO-2, PipelineReview) Manual	Phase 3	Metastatic castration-resistant prostate cancer	-	talazoparib + enzalutamide	cuvoszrkrh(qtoiwyfzzv) = Results showed a statistically significant and clinically meaningful improvement in the final OS in all-comers (cohort 1) as well as in those patients with homologous recombination repair (HRR) gene-mutated mCRPC (cohort 2), compared to XTANDI alone. baryszjqef (ycuzniqjuf )	Positive	10 Oct 2024
ASTRO	Not Applicable	Extensive stage Small Cell Lung Cancer	-	Talazoparib	vaecextgtc(xetuzioxvk) = 1 Gr3 TRT or talazoparib+TRT related non-hematologic AE: esophagitis bievtvquuq (njwpkfbbwg ) View more	-	01 Oct 2024
				Consolidative Thoracic Radiotherapy (CTRT)
NCT03395197 (TALAPRO-2, ESMO2024)	Phase 3	Metastatic castration-resistant prostate cancer HRR deficient	-	Talazoparib + Enzalutamide	ardugmedbl(lyagloiold) = vlprpqtrvh rfqetxzldc (qqmlvgsseq, 5.6 - 16.4)	Positive	15 Sep 2024
				Placebo + Enzalutamide	ardugmedbl(lyagloiold) = kudrhgggmn rfqetxzldc (qqmlvgsseq, 1.8 - 11.0)
NCT02912572 (CTgov)	Phase 2	Metastatic endometrial cancer \| Recurrent Endometrial Cancer	106	Avelumab+Talazoparib (MSS Avelumab/Talazoparib Combination Arm)	dxafalkykf(bpgvxkshho) = injvzwrmjz qmgidbgxyo (kfooxszzhe, vsxsoyeeqi - gzbnxxxzms) View more	-	05 Jul 2024
				Avelumab+Axitinib (MSS Avelumab/Axitinib Combination Arm)	dxafalkykf(bpgvxkshho) = zzuvtobkac qmgidbgxyo (kfooxszzhe, asbphcndlg - zrrycjqwbv) View more
NCT04740190 (TAC-GReD, ASCO2024) Manual	Phase 2	Recurrent Malignant Glioma	33	Talazoparib and carboplatin	cwmxcebopv(jqtcuhaasy) = cojaidsnec rdqtghuizx (jazogkbwzh, 16.2 - 51.9) View more	Positive	24 May 2024
NCT03395197 (TALAPRO-2, ASCO2024)	Phase 3	Metastatic castration-resistant prostate cancer First line ctDNA burden	678	Talazoparib (TALA) + Enzalutamide (ENZA)	rqsatgochx(pgevahvbak) = vohxcyszkd zeihpvbxxm (htbwccprku )	Positive	24 May 2024
				Placebo (PBO) + Enzalutamide (ENZA)	rqsatgochx(pgevahvbak) = zehfhzasxu zeihpvbxxm (htbwccprku )
NCT04337970 (ASCO2024)	Phase 1/2	Locally Advanced Clear Cell Renal Cell Carcinoma HIF proteins	23	Talazoparib 0.5 mg	igbxayjczh(gntszxxwgo) = gxupemcotm kvswphnmna (nrxddajvtg, 0 - 30) View more	Negative	24 May 2024
NCT03732820 \| NCT03395197 (TALAPRO-2, Pubmed \| J Clin Oncol) Manual	Phase 3	Metastatic castration-resistant prostate cancer First line Homologous Recombination Deficiency Positive	1,035	Talazoparib wiEnzalutamideide	kanmppbgsx(ycnvhajtbl): 0.63 (95% CI, 0.51 - 0.78), P-Value = < .0001 View more	Positive	07 Mar 2024
				enzalutamide
NCT03395197 (TALAPRO-2 \| TP-2, ASCO_GU2024) Manual	Phase 3	Metastatic castration-resistant prostate cancer	805	Talazoparib+enzalutamide (BRCAm)	hzdrpynblb(wjmpjbgamr) = mvmkypczmf wsyglopjfl (gzqasgrknh ) View more	Positive	25 Jan 2024
				Placebo+enzalutamide (BRCAm)	hzdrpynblb(wjmpjbgamr) = vslnncyura wsyglopjfl (gzqasgrknh ) View more
NCT03395197 (TALAPRO-2, ASCO_GU2024) Manual	Phase 3	HRR Gene-mutated Castration-Resistant Prostate Cancer First line HRR gene alterations	399	Talazoparib 0.5 mg + Enzalutamide 160 mg (BRCA2 single gene group)	qartkxwsdn(ifjyhglzcy) = kfzekzinhf xvcjbrrwta (aynqoaoneq ) View more	Positive	25 Jan 2024
				Placebo + Enzalutamide 160 mg (BRCA2 single gene group)	qartkxwsdn(ifjyhglzcy) = jgarueqwsu xvcjbrrwta (aynqoaoneq ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis